logo

Ultragenyx Pharmaceutical Inc (RARE)



Trade RARE now with
  Date
  Headline
5/17/2018 8:31:39 AM Ultragenyx Pharma Says Phase 3 Study Of Crysvita Meets Primary Endpoint
5/8/2018 8:41:16 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) FY18 Rev. Estimate To 40.4 M From 243.4 M
5/8/2018 8:41:05 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q4 18 Rev. Estimate To 12.1 M From 13.4 M
5/8/2018 8:40:53 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q3 18 Rev. Estimate To 10.5 M From 76.6 M
5/8/2018 8:40:41 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q2 18 Rev. Estimate To 7.1 M From 8.0 M
5/8/2018 8:40:09 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) FY18 Estimate To -4.48 From -4.06
5/8/2018 8:39:49 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q4 18 Estimate To -2.19 From -2.05
5/8/2018 8:39:32 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q3 18 Estimate To -0.82 From -0.70
5/8/2018 8:39:17 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q2 18 Estimate To -2.10 From -1.99
5/7/2018 4:08:03 PM Ultragenyx Pharmaceutical Q1 EPS $0.62 Vs. Loss $1.63 Year Ago
4/30/2018 8:34:59 AM Ultragenyx And Kyowa Kirin Announce Crysvita Launched In U.S. For The Treatment Of XLH In Children And Adults
4/23/2018 8:35:42 AM Ultragenyx Announces Filing And FDA Clearance Of IND Application For DTX401
3/7/2018 8:03:17 AM Ultragenyx Unveils Positive Topline Results, DMC Review From First Cohort Of Phase 1/2 Clinical Study Of DTX301
2/21/2018 7:27:04 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) FY18 Estimate To -4.15 From -4.06
2/21/2018 7:26:47 AM Wedbush Is Increasing Ultragenyx Pharmaceutical Inc (RARE) Q3 18 Estimate To -0.68 From -0.71